Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Evolva Holding SA
  6. News
  7. Summary
    EVE   CH0021218067

EVOLVA HOLDING SA

(EVE)
  Report
Delayed Swiss Exchange  -  11:30:43 2023-02-06 am EST
0.0868 CHF   -3.02%
01/11Swiss Biotech Evolva Exceeds FY22 Revenue Growth Target With 57% Jump
MT
01/11Evolva delivers strong results with 57% revenue growth and increasing margins
EQ
2022Evolva launches its Natural Nootkatone
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Evolva provides financial and project update

02/09/2015 | 01:05am EST

Evolva provides financial and project update

9 February 2015 - Evolva (SIX: EVE) today provides a financial and project update.

According to the provisional, unaudited financials, revenues in 2014 slightly exceeded CHF 10 million (in line with guidance), whilst the year-end cash position of CHF 60.7 million was higher than the CHF 50 million projected in November 2014. This positive deviation is primarily due to transactions related to the acquisition of Allylix in December: the USD 4 million investment by Cargill and the sale of 6 million shares to cover Allylix liabilities that was executed earlier than expected (in December 2014). A major part of the proceeds from the share sale was used in January 2015 to settle the remaining Allylix liabilities. After adjusting for the above two factors, cash at year-end was about CHF 52.5 million compared with our guidance of CHF 50 million. Cash outflow from operations in 2014 developed in line with the November guidance ("about CHF 20 million").

In 2015, we expect revenues to increase on 2014. Product related revenues will contribute for the first time, however a significant majority of revenues will still derive from partnerships. Due to investment in manufacturing and commercialisation of key products, in particular stevia, resveratrol and nootkatone, our operating cash outflow will increase in 2015.

We expect the recent appreciation of the Swiss Franc to be modestly positive for Evolva in the short term, given that we have significant costs in other currencies. The beneficial cost impact outweighs some negative effect on revenues.

On stevia, a decision on exercising our option to participate up to 45% in Cargill's fermented stevia business is expected in the first half of 2015. We expect that stevia will be launched in 2016.

The portfolio review initiated after the Allylix acquisition is ongoing and is expected to conclude with respect to our major products in March 2015.

Evolva will publish its audited financial statements for 2014, as well as a more detailed financial outlook for 2015, on Tuesday 31 March 2015. The Annual General Meeting will take place on Tuesday 12 May 2015 in the morning in Basel, Switzerland.

- ends -

About Evolva Holding SA

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva's products include stevia, vanillin, nootkatone, valencene, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video.

Contact Details

Neil Goldsmith, CEO

Jakob Dynnes Hansen, CFO

Paul Verbraeken, IR

neilg@evolva.com

jakobdh@evolva.com

paulv@evolva.com

+ 41 61 485 2005

+ 41 61 485 2034

+ 41 61 485 2035

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.




Provider
Channel
Contact
Tensid Ltd., Switzerland
www.tensid.ch


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
marco@tensid.ch
+41 41 763 00 50
All news about EVOLVA HOLDING SA
01/11Swiss Biotech Evolva Exceeds FY22 Revenue Growth Target With 57% Jump
MT
01/11Evolva delivers strong results with 57% revenue growth and increasing margins
EQ
2022Evolva launches its Natural Nootkatone
EQ
2022Evolva Holding SA Launches Its Natural Nootkatone
CI
2022Evolva Predicts No Impact From Swiss Bourse's Fine For Breaching Reporting Rules
MT
2022Biotechnology Group Evolva Fined by SIX Swiss for Breach of Accounting Standard
MT
2022Evolva statement to SER communication
EQ
2022Evolva Achieves Milestones For Resveratrol Across Core Dietary Supplement Markets
MT
2022Evolva : Update on activities to boost Resveratrol
EQ
2022Evolva Gets Brazilian Nod For Veri-te Resveratrol Dietary Supplements In Animals
MT
More news
Analyst Recommendations on EVOLVA HOLDING SA
More recommendations
Financials
Sales 2022 15,0 M 16,2 M 16,2 M
Net income 2022 -42,2 M -45,5 M -45,5 M
Net cash 2022 8,98 M 9,69 M 9,69 M
P/E ratio 2022 -
Yield 2022 -
Capitalization 97,2 M 105 M 105 M
EV / Sales 2022 5,87x
EV / Sales 2023 3,74x
Nbr of Employees 62
Free-Float 97,6%
Chart EVOLVA HOLDING SA
Duration : Period :
Evolva Holding SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOLVA HOLDING SA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 0,09
Average target price
Spread / Average Target -
Managers and Directors
Christian Wichert Chief Executive Officer
Beat In-Albon Chairman
Astrid Schńfer Head-Research & Development
Gerhard Lobmaier Chief Operating Officer
Nic Buergin Secretary, Head-Legal & Compliance
Sector and Competitors
1st jan.Capi. (M$)
EVOLVA HOLDING SA9.15%108
MODERNA, INC.-3.55%66 559
LONZA GROUP AG21.92%44 368
IQVIA HOLDINGS INC.15.76%44 054
ALNYLAM PHARMACEUTICALS, INC.-1.80%28 711
SEAGEN INC.7.38%25 622